諾誠健華(09969.HK)抑制劑新藥研究申請獲國家藥監局受理
諾誠健華(09969.HK)公布,旗下新型多靶點受體酪氨酸激(酉每)抑制劑ICP-033,新藥研究申請已獲國家藥品監督管理局受理。
該產品為公司具有全球自主知識產權的1類創新藥,計劃單用或/和免疫療法及其他靶向藥聯合治療肝癌、腎細胞癌、大腸癌及其他實體腫瘤,可抑制腫瘤血管形成,改善腫瘤微環境,抑制腫瘤生長、侵襲和轉移,從而發揮靶點特異性抗腫瘤作用。
諾誠健華聯合創始人、董事長兼CEO崔霽松表示,ICP-033為公司第六個進入臨床階段的創新藥,將進一步豐富實體瘤領域的產品管線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.